share_log

RedChip Interviews Inspira Technologies' CFO Joe Hayon

RedChip Interviews Inspira Technologies' CFO Joe Hayon

红筹公司采访Inspira技术公司首席财务官乔·海恩
Accesswire ·  2022/06/30 09:05

ORLANDO, FL / ACCESSWIRE / June 30, 2022 / RedChip Companies will air a new C-Level interview with Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies") on The RedChip Money Report® on Bloomberg TV, this Saturday, July 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

佛罗里达州奥兰多/ACCESSWIRE/2022年6月30日/红筹公司将于本周六,7月2日晚7点在彭博电视台播出对Inspira Technologies Oxy B.H.N.Ltd.(纳斯达克代码:IINN)(纳斯达克代码:IINNW)(以下简称“公司”或“Inspira科技公司”)的新一轮C级访谈。东部时间(ET)。据估计,全美约有7300万个家庭可以收看彭博电视。

RedChip's CEO Dave Gentry interviews Inspira™ Technologies' CFO Joe Hayon in this exclusive interview, covering the questions on the mind of current and future shareholders.

红筹公司首席执行官戴夫·金特里在这次独家专访中采访了Inspira™技术公司的首席财务官乔·海恩,涵盖了当前和未来股东心中的问题。

Access this interview in its entirety at

访问此访谈全文,请访问

Inspira™ Technologies is redefining artificial respiration with its breakthrough Augmented Respiration Technology (ART) system, a minimally invasive, scalable and cost-effective early-stage respiratory support system that is designed to utilize direct blood oxygenation in awake patients, rebalancing oxygen saturation levels in minutes in order to minimize the need for intubation, induced coma, and invasive mechanical ventilation treatment.

Inspira™科技公司正在重新定义人工呼吸,其突破性的增强呼吸技术(ART)系统是一种微创、可扩展且经济高效的早期呼吸支持系统,旨在利用清醒患者的直接血液氧合,在几分钟内重新平衡氧饱和度水平,以最大限度地减少插管、诱导昏迷和侵入性机械通气治疗的需要。

Inspira Technologies is targeting the millions of acute respiratory failure patients each year for treatment with the ART™ system¹. The Company's go-to-market strategy includes aiming to establish multiple recurring revenue streams across medical sectors and markets.

Inspira科技公司针对每年数以百万计的急性呼吸衰竭患者使用ART™系统?进行治疗。该公司的入市战略包括致力于在医疗部门和市场建立多种经常性收入流。

The ART's design supports the Company's strategic business model to encourage the extension of acute respiratory care beyond the ICU and into General Medical Units. Inspira Technologies is actively pursuing regulatory approvals in the U.S. (primary) and Europe (secondary) and is targeting up to $401 million in potential sales through its existing, and previously announced, agreements. The Company's pipeline is anticipated to continue to grow as it pursues collaborations with leading hospitals and professional associations for regional deployments. Additional opportunities for value creation include collaborations with strategic partners, such as global medical device companies and multinational electronics contract manufacturers, which may acquire primary components of the ART.

ART的设计支持该公司的战略商业模式,鼓励将急性呼吸护理扩展到ICU以外的普通医疗单位。Inspira技术公司正在积极寻求美国(主要)和欧洲(次要)监管机构的批准,并计划通过其现有的和之前宣布的协议,实现高达4.01亿美元的潜在销售额。随着该公司寻求与领先医院和专业协会合作进行地区性部署,该公司的渠道预计将继续增长。其他创造价值的机会包括与战略合作伙伴的合作,例如全球医疗设备公司和跨国电子产品合同制造商,它们可能会收购ART的主要组成部分。

Interview highlights:

采访亮点:

In the exclusive RedChip Money Report interview, Hayon discusses the Company's potentially game-changing technology, acute respiratory failure patient market statistics, FDA approval plans, and much more.

在RedChip Money Report独家访谈中,Hayon讨论了该公司可能改变游戏规则的技术、急性呼吸衰竭患者市场统计数据、FDA批准计划等。

Access this interview in its entirety at

访问此访谈全文,请访问

About The RedChip Money Report®

关于红筹资金报告®

The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experience focused on Discovering Tomorrow's Blue Chips Today™. "The RedChip Money Report®" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

红筹资金报告®由红筹公司制作,该公司是一家国际投资者关系和媒体公司,拥有30年的经验,专注于今天发现明天的蓝筹股™.《红筹资金报告》(The RedChip Money Report®)提供了关于小盘股投资的精辟评论、华尔街分析师的采访、金融书评以及对上市公司高管的专题采访。

About Inspira™ Technologies

关于Inspira™技术

Inspira Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (ART), designed to rebalance patient oxygen saturation levels. The Company's ART technology potentially allows patients to remain awake during treatment while minimizing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The Company's product has not yet been tested or used in humans and has not been approved by any regulatory entity.

Inspira Technologies是一家在呼吸治疗领域创新的医疗技术公司。该公司开发了一种突破性的增强呼吸技术(ART),旨在重新平衡患者的血氧饱和度水平。该公司的ART技术有可能使患者在治疗期间保持清醒,同时最大限度地减少对需要插管和药物诱导昏迷的高度侵入性、高风险和昂贵的机械通风系统的需求。该公司的产品尚未在人体上进行测试或使用,也未获得任何监管实体的批准。

For more information, please visit our corporate website:

欲了解更多信息,请访问我们的公司网站:

About RedChip Companies

关于红筹公司

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Money Report," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

红筹公司是一家拥有5000美元股份的公司,是一家专注于微市值和小盘股公司的国际投资者关系、媒体和研究公司。30年来,红筹为客户提供了具体、可衡量的结果。我们的时事通讯《红筹资金报告》每周在线发送给60,000名投资者。红筹为小盘股和小盘股公司开发了业内最全面的服务平台。这些服务包括:其股票研究的全球分销网络;在美国主要城市的零售和机构路演;面向股票经纪人、RIA、机构和家族理财室的对外营销;已产生数百万独特投资者观点的数字媒体投资者关系平台;投资者网络研讨会和团体电话会议;每周在彭博美国播出的电视节目“红筹资金报告”;本地和全国市场的电视广告;企业和产品视频;网站设计;以及传统投资者关系服务,其中包括新闻稿撰写、投资者演示文稿的开发、季度电话会议脚本编写、战略咨询、融资等。

To learn more about RedChip's products and services, please visit:

要了解更多有关红筹公司产品和服务的信息,请访问:

"Discovering Tomorrow's Blue Chips Today"™

《今日发现明天的蓝筹股》™

Forward Looking Statements

前瞻性陈述

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, the Company is using forward-looking statements when it discusses its goals and that Yeheskely-Hayon's experience the field of blood oxygenation and ECMO devices will contribute to the development of the Company's ART system. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Registration Statement on Form F-1 filed with the SEC, as well as its subsequent public filings, which are available on the SEC's website, www.sec.gov.

本新闻稿包含符合美国联邦证券法的明示或暗示的前瞻性陈述。例如,该公司在讨论其目标时使用前瞻性陈述,耶斯凯利-海恩在血液氧合和ECMO设备领域的经验将有助于公司ART系统的发展。这些前瞻性陈述及其影响仅基于公司管理层目前的预期,受许多因素和不确定因素的影响,这些因素和不确定性可能导致实际结果与前瞻性陈述中所描述的大不相同。除非法律另有要求,否则公司没有义务公开发布对这些前瞻性陈述的任何修订,以反映本前瞻性陈述之后发生的事件或情况,或反映意外事件的发生。有关影响公司的风险和不确定因素的更详细信息,请参见公司提交给美国证券交易委员会的F-1表格注册说明书中的“风险因素”标题以及公司随后提交的公开文件,这些文件可在美国证券交易委员会的网站www.sec.gov上查阅。

Contact:

联系方式:

Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
IINN@redchip.com

戴夫·金特里
红筹公司。
1-800-红筹(733-2447)
或407-491-4498
邮箱:iinn@redchip.com

--END--

--完

SOURCE: RedChip

资料来源:红筹公司


View source version on accesswire.com:
在accesswire.com上查看源代码版本:

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发